One in 10 people with atopic dermatitis, the most common type of eczema, have symptoms on their feet. These quick facts can help you manage it.

Patients with higher-severity alopecia areata (AA) have a higher prevalence and incidence of comorbid atopic dermatitis (AD), ...

Findings from a recent phase 3b/4 study of upadacitinib support a treat-to-target strategy for dose escalation or reduction ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Apogee Therapeutics, Inc. (NASDAQ:APGE) is one of the 11 Hot New Stocks to Invest in Now. On July 7, analyst Edward Nash of ...

Turn Therapeutics today announced the initiation of a randomized, double-blind, vehicle-controlled clinical trial evaluating its topical GX-03 formulation -- previously used in the company's advanced ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Any physical activity can be beneficial for eczema, as long as you’re choosing the right clothing and practicing good habits ...

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...

Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...

Certain pain-related pruritus descriptors may independently predict mental health outcomes, sleep disturbance, and QOL reduction in patients with AD.